Drugs / SB692342
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01098474 | Jul 2010 → Apr 2011 | tuberculosis | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SB692342 | “Subjects received two doses of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh” NCT01098474 ↗ |
| Known as | 692342 | “GSK's investigational vaccine 692342” NCT01098474 ↗ |
| Modality | Vaccine | “candidate tuberculosis vaccine (692342)” NCT01098474 ↗ |
| Route | Intramuscular | “administered intramuscularly in the anterolateral region of the right thigh” NCT01098474 ↗ |